The return on investment of a Medicaid tobacco cessation program in Massachusetts
- PMID: 22238633
- PMCID: PMC3253087
- DOI: 10.1371/journal.pone.0029665
The return on investment of a Medicaid tobacco cessation program in Massachusetts
Abstract
Background and objective: A high proportion of low-income people insured by the Medicaid program smoke. Earlier research concerning a comprehensive tobacco cessation program implemented by the state of Massachusetts indicated that it was successful in reducing smoking prevalence and those who received tobacco cessation benefits had lower rates of in-patient admissions for cardiovascular conditions, including acute myocardial infarction, coronary atherosclerosis and non-specific chest pain. This study estimates the costs of the tobacco cessation benefit and the short-term Medicaid savings attributable to the aversion of inpatient hospitalization for cardiovascular conditions.
Methods: A cost-benefit analysis approach was used to estimate the program's return on investment. Administrative data were used to compute annual cost per participant. Data from the 2002-2008 Medical Expenditure Panel Survey and from the Behavioral Risk Factor Surveillance Surveys were used to estimate the costs of hospital inpatient admissions by Medicaid smokers. These were combined with earlier estimates of the rate of reduction in cardiovascular hospital admissions attributable to the tobacco cessation program to calculate the return on investment.
Findings: Administrative data indicated that program costs including pharmacotherapy, counseling and outreach costs about $183 per program participant (2010 $). We estimated inpatient savings per participant of $571 (range $549 to $583). Every $1 in program costs was associated with $3.12 (range $3.00 to $3.25) in medical savings, for a $2.12 (range $2.00 to $2.25) return on investment to the Medicaid program for every dollar spent.
Conclusions: These results suggest that an investment in comprehensive tobacco cessation services may result in substantial savings for Medicaid programs. Further federal and state policy actions to promote and cover comprehensive tobacco cessation services in Medicaid may be a cost-effective approach to improve health outcomes for low-income populations.
Conflict of interest statement
Figures
Similar articles
-
A longitudinal study of medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in hospitalizations for cardiovascular disease.PLoS Med. 2010 Dec 7;7(12):e1000375. doi: 10.1371/journal.pmed.1000375. PLoS Med. 2010. PMID: 21170313 Free PMC article.
-
Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in smoking prevalence.PLoS One. 2010 Mar 18;5(3):e9770. doi: 10.1371/journal.pone.0009770. PLoS One. 2010. PMID: 20305787 Free PMC article.
-
The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.Am J Health Promot. 2011 Sep-Oct;26(1):e11-23. doi: 10.4278/ajhp.101014-QUAN-337. Am J Health Promot. 2011. PMID: 21879928
-
Cost-effectiveness of population-level proactive tobacco cessation outreach among socio-economically disadvantaged smokers: evaluation of a randomized control trial.Addiction. 2019 Dec;114(12):2206-2216. doi: 10.1111/add.14752. Epub 2019 Sep 4. Addiction. 2019. PMID: 31483549 Free PMC article.
-
Medicaid Tobacco Cessation: Big Gaps Remain In Efforts To Get Smokers To Quit.Health Aff (Millwood). 2016 Jan;35(1):62-70. doi: 10.1377/hlthaff.2015.0756. Health Aff (Millwood). 2016. PMID: 26733702 Free PMC article.
Cited by
-
Estimating the return on investment of the New York Tobacco Control Programme: a synthetic control study.BMJ Open. 2024 Apr 2;14(4):e080525. doi: 10.1136/bmjopen-2023-080525. BMJ Open. 2024. PMID: 38569704 Free PMC article.
-
Cost-Effectiveness of a Comprehensive Primary Care Smoking Treatment Program.Am J Prev Med. 2024 Mar;66(3):435-443. doi: 10.1016/j.amepre.2023.10.011. Epub 2023 Oct 14. Am J Prev Med. 2024. PMID: 37844710 Clinical Trial.
-
Examining Racial/Ethnic Disparities in Tobacco Dependence Treatment Among Medicaid Beneficiaries Using Fifty State Medicaid Claims, 2009-2014.J Racial Ethn Health Disparities. 2024 Apr;11(2):755-763. doi: 10.1007/s40615-023-01558-w. Epub 2023 Jun 16. J Racial Ethn Health Disparities. 2024. PMID: 37326794
-
Rates of Tobacco Use Disorder, Pharmacologic Treatment, and Associated Mental Health Disorders in a Medicaid Claim Review Among Youth in Indiana, USA.Tob Use Insights. 2022 Aug 27;15:1179173X221119133. doi: 10.1177/1179173X221119133. eCollection 2022. Tob Use Insights. 2022. PMID: 36052177 Free PMC article.
-
Prescription Smoking-Cessation Medication Fills and Spending, 2009-2019.Am J Prev Med. 2022 Jun;62(6):e351-e355. doi: 10.1016/j.amepre.2021.11.021. Epub 2022 Mar 28. Am J Prev Med. 2022. PMID: 35597571 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Vital signs: Current cigarette smoking among adults aged ≥18 years—United States, 2009. MMWR. 2010;59(35):1135–1140. - PubMed
-
- Centers for Disease Control and Prevention. State-specific smoking-attributable mortality and years of potential life lost—United States, 2000–2004. MMWR. 2009;58(02):29–33. - PubMed
-
- Centers for Disease Control and Prevention. Adult cigarette smoking in the United States: current estimate. 2009. Available: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_sm.... Accessed 2011 Aug 05.
-
- Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR. 2008;57(45):1226–28. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical

